Inhibition of SLC7A11 by erastin also increased the sensitivity of cisplatin in cancer cells (19, 45), suggesting the combination of erastin and chemotherapeutical reagents can be sufficient for cancer therapy. Here, SLC7A11 is linked to cancer.